Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2011 Standout
Final Version of 2009 AJCC Melanoma Staging and Classification
2009 Standout
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
A discrete choice experiment of preferences for genetic counselling among Jewish women seeking cancer genetics services
2006
The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial
2009
Anti-cancer natural products isolated from chinese medicinal herbs
2011 Standout
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials
2003
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
2010 StandoutNobel
Breast cancer
2016 Standout
Inhibition of α4 integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with Gambogic acid
2008
Relaxin‐like peptides in cancer
2003
Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation
2004 Standout
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments
2002
Current systemic therapy for metastatic melanoma
2009
Wage Losses in the Year After Breast Cancer: Extent and Determinants Among Canadian Women
2008
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
2010
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
2013 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
New applications of cancer immunotherapy
2002
CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
2011 StandoutNobel
Early stage breast cancer: costs and quality of life one year after treatment by mastectomy or conservative surgery and radiation therapy
2000
Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group
2002
Return-to-work interventions integrated into cancer care: a systematic review
2010 Standout
Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force
2011 Standout
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab
2008
Measuring Quality of Life in Cosmetic and Reconstructive Breast Surgery: A Systematic Review of Patient-Reported Outcomes Instruments
2007
Perturbations of both nonregulatory and regulatory FOXP3+ T cells in patients with malignant melanoma
2010 StandoutNobel
Management of Metastatic Melanoma 2005
2006
Checkpoint Blockade in Cancer Immunotherapy
2006 StandoutNobel
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
2005 Standout
Development of a New Patient-Reported Outcome Measure for Breast Surgery: The BREAST-Q
2009 Standout
Perioperative Screening for Metastatic Disease is not Indicated in Patients with Primary Breast Cancer and no Clinical Signs of Tumor Spread
2003
Natural compounds for cancer treatment and prevention
2009 Standout
Body Image in Younger Breast Cancer Survivors
2015 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Biomarkers for epithelial-mesenchymal transitions
2009 Standout
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Interaction between integrin α5 and fibronectin is required for metastasis of B16F10 melanoma cells
2005
Modes of resistance to anti-angiogenic therapy
2008 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Perspectives in cancer chemotherapy
2001
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival
2012
Antitumor activity of imidazole derivatives: dacarbazine and the new alkylating agent imidazene (Review)
2010
Azole-Based Energetic Salts
2011 Standout
Relaxin Augments BMP-2–Induced Osteoblast Differentiation and Bone Formation
2014 Standout
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
2014 StandoutNobel
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
1999 Standout
Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma
2003
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade
2017 StandoutNobel
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
1999
Works of S. Verma being referenced
Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs
1999
Estimates of the lifetime costs of breast cancer treatment in Canada
2000
Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing
2001
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
1996
2103 ORAL A randomized, double-blind phase 2 study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)
2007